23 patents
Utility
Novel Disintegration Oral Film Formulation with a Controlled or Sustained Active Release
21 Dec 23
Oral film formulations comprising at least one hydrophobic active agent; and a polymeric matrix at least partly composed of hydrophobic or insoluble excipients, or a combination thereof, to facilitate a controlled or sustained dissolution.
Billal TIR, Carolin MADWAR, Nadine PAIEMENT
Filed: 9 Jun 23
Utility
Method of Preparing Loxapine Film Oral Dosage Form
10 Aug 23
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system.
Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
Filed: 24 Mar 23
Utility
Oral Films with Flavor Entrapment
20 Jul 23
Pharmaceutical compositions employing flavor entrapment to mitigate the unpleasant taste of active agents are described.
Billal TIR, Nadine PAIEMENT
Filed: 18 Jan 23
Utility
Lipophilic Active Oral Film Formulation and Method of Making the Same
29 Jun 23
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP.
Carolin MADWAR, Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Erick GONZALEZ-LABRADA
Filed: 16 Feb 23
Utility
Loxapine film oral dosage form
16 May 23
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system.
Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
Filed: 2 Aug 18
Utility
Lipophilic active oral film formulation and method of making the same
14 Mar 23
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P.
Carolin Madwar, Nadine Paiement, Rodolphe Obeid, Justin Conway, Erick Gonzalez-Labrada
Filed: 15 Apr 19
Utility
Oral Film Formulation for Modulating Absorption Profile
16 Feb 23
An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent.
Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Billal TIR
Filed: 25 Sep 22
Utility
Stable Tryptamine Oral Films
29 Dec 22
Pharmaceutical compositions with tryptamines having enhanced active stability properties are described.
Mobarik BILAL, Nadine PAIEMENT
Filed: 16 Jun 22
Utility
Method of Treatment and Device for the Improved Bioavailability of Leukotriene Receptor Antagonists
15 Dec 22
Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists.
Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID, Ludwig AIGNER, Johanna MICHAEL
Filed: 28 Apr 22
Utility
Method of Treatment and Device for the Improved Bioavailability of Leukotriene Receptor Antagonists
17 Nov 22
Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists.
Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID
Filed: 26 Apr 22
Utility
Oral film formulation for modulating absorption profile
18 Oct 22
An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent.
Nadine Paiement, Rodolphe Obeid, Justin Conway, Billal Tir
Filed: 5 Oct 20
Utility
Lipophilic Active Oral Film Formulation and Method of Making the Same
23 Dec 21
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P.
Carolin MADWAR, Nadine PAIEMENT, Rodolphe OBEID, Justin W. CONWAY, Erick GONZALEZ-LABRADA
Filed: 4 Nov 19
Utility
Film Dosage Form with Extended Release Mucoadhesive Particles
14 Oct 21
An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film.
Rodolphe Obeid, Nadine Paiement, Erick Gonzalez-Labrada
Filed: 14 Jun 21
Utility
Film dosage form with extended release mucoadhesive particles
15 Jun 21
An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film.
Rodolphe Obeid, Nadine Paiement, Erick Gonzalez-Labrada
Filed: 23 Aug 18
Utility
Oral Film Formulation for Modulating Absorption Profile
28 Jan 21
An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent.
Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Billal TIR
Filed: 5 Oct 20
Utility
Oral film formulation for modulating absorption profile
9 Nov 20
An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent.
Nadine Paiement, Rodolphe Obeid, Justin W. Conway, Billal Tir
Filed: 27 Sep 18
Utility
Device and method of treating conditions associated with neuroinflammation
27 Jul 20
Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene.
Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
Filed: 4 Mar 18
Utility
Solid Oral Film Dosage Forms and Methods for Making Same
8 Jul 20
Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.
Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid, Laetitia Rodes, Billal Tir
Filed: 16 Mar 20
Utility
Lipophilic Active Oral Film Formulation and Method of Making the Same
6 May 20
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P.
Carolin Madwar, Nadine Paiement, Rodolphe Obeid, Justin Conway, Erick Gonzalez-Labrada
Filed: 14 Apr 19
Utility
Lipophilic Active Oral Film Formulation and Method of Making the Same
6 May 20
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP.
Nadine Paiement, Justin W. Conway, Carolin Madwar
Filed: 5 Nov 19